Global Immunotherapy Drugs Market, By Type of Drug (Monoclonal Antibodies, Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha and Beta, Interleukins and Other Drugs), Therapy Area (Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases and Other Therapy Areas), End User (Hospitals, Clinics and Other End Users)-Industry Trends and Forecast to 2029
Market Analysis and Size
Pembrolizumab, a PD-1 inhibitor manufactured by Merck & Co., Inc., holds a strong lead among top players of immunotherapy drugs on the market. According to a study published in the International Journal of General Medicine in 2018, mortality from many non-communicable diseases (NCDs) or chronic diseases continues to rise around the world, with a disproportionately larger impact in low-middle income countries (LMIs), with chronic diseases accounting for nearly 75% of global deaths.
“Monoclonal antibodies” segment of the type of drug hold the largest share of the immunotherapy drugs market due to their high specificity and fewer adverse effects, as well as an increased focus on tailored therapies, industry activities, and the growing prevalence and patient pool of target diseases. Data Bridge Market Research analyses that the immunotherapy drugs market was valued at USD 181.75 billion in 2021 and is further estimated to reach USD 434.18 billion by 2029, and is expected to grow at a CAGR of 11.5% during the forecast period of 2022 to 2029.
Report Scope and Market Segmentation
2022 to 2029
2020 (Customizable to 2019 - 2014)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Type of Drug (Monoclonal Antibodies, Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha and Beta, Interleukins and Other Drugs), Therapy Area (Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases and Other Therapy Areas), End User (Hospitals, Clinics and Other End Users)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Abbott (US), PerkinElmer Inc. (US), Illumina, Inc. (US), QIAGEN (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), AstraZeneca (UK), Pfizer Inc. (US), Sanofi (France), Johnson & Johnson Services, Inc. (India), AbbVie Inc. (US), Allergan (Ireland), Merck & Co., Inc. (US), Amgen Inc. (US), Thermo Fisher Scientific (US), Teva Pharmaceutical Industries Ltd. (Israel), Takeda Pharmaceutical Company Limited. (Japan), GlaxoSmithKline plc (UK), Lupin Pharmaceuticals, Inc. (US), Lilly (US), Bristol-Myers Squibb Company (US), Medtronic (US), Bayer AG (Germany) and Boehringer Ingelheim International GmbH (Germany).
Immunotherapy drugs are used to boost or decrease the body's immune system. They are mostly used to treat cancer and work by stimulating the body's immune system and triggering an immunological response that aids in the generation of antibodies. Antibodies that are created in response to an antigen kill malignant or tumour cells.
Epigenetics Market Dynamics
Major factors that are expected to boost the growth of the immunotherapy drugs market in the forecast period are as follows:
- Rise in the adoption of immunotherapy drugs over conventional treatment regimens
Immunotherapies as an additional therapy in severe COVID-19 instances, according to research investigations. Immunotherapies based on inflammatory cytokine neutralisation, immunomodulation, and passive viral neutralisation can reduce inflammation, inflammation-associated lung damage, and viral load while also avoiding ICU admission and mechanical ventilation which will further accelerate the market growth.
- Increase in the cancer and autoimmune and infectious diseases
According to the National Cancer Institute, around 1,735, 350 new cancer cases were diagnosed in the United States in 2018. Each year, there are 439.2 new cancer cases per 100,000 men and women which is further anticipated to propel the growth of the immunotherapy drugs market.
- Growing need for monoclonal antibodies and biosimilars
Monoclonal antibodies are beneficial because they allow researchers to create antibodies that target a single tumour antigen. In vitro techniques in the laboratory can be used to make multiple copies of the antibodies. Biosimilars are critical in the treatment of cancer is further con which will further contribute to the market growth.
In addition, the growing demand for personalized medicines and increasing advancement of affordable nanoparticles for deploying immunotherapies are further provide potential opportunities for the growth of the immunotherapy drugs market in the coming years.
On the other hand, the timeline issues, side-effects, and manufacturing difficulties is further projected to impede the growth of the immunotherapy drugs market in the targeted period. However, the increased prices of immunotherapy treatment, regional disparities, and dearth of insurance coverage might further challenge the growth of the immunotherapy drugs market in the near future.
This immunotherapy drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the immunotherapy drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Covid-19 Impact on Immunotherapy Drugs Market
The COVID-19 had a positive impact on the immunotherapy drugs market. Because several businesses are actively engaged on creating immunotherapy-based medications or vaccines for COVID-19, the influence of COVID-19 on the immunotherapy drugs industry is positive. BioNTech SE is now undertaking a phase III clinical research in healthy volunteers to examine the safety, tolerability, and immunogenicity of BNT162b2 against COVID-19 in partnership with Pfizer Inc.
- In 2019, in patients with relapsed or refractory diffuse large B-cell lymphoma, Gilead Sciences, Inc. and Humanigen, Inc. (US) cooperated to perform a study using lenzilumab in combination with YESCARTA.
Global Immunotherapy Drugs Market Scope and Market Size
The immunotherapy drugs market is segmented on the basis of type of drug, therapy area and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type of Drug
- Monoclonal Antibodies
- Adult Vaccines
- Checkpoint Inhibitors
- Interferons Alpha and Beta
- Other Drugs
On the basis of type of drug, the immunotherapy drugs market is segmented into monoclonal antibodies, adult vaccines, checkpoint inhibitors, interferons alpha and beta, interleukins and other drugs. Adult vaccines is further sub segmented into preventive vaccines and therapeutic vaccines. Interleukins is further sub segmented inyonon-specific immunotherapy and adaptive cell therapy.
- Autoimmune and Inflammatory Diseases
- Infectious Diseases
- Other Therapy Areas
On the basis therapy area, the immunotherapy drugs market is segmented into cancer, autoimmune and inflammatory diseases, infectious diseases and other therapy areas.
- Other End Users
On the basis of end user, the immunotherapy drugs market is segmented into hospitals, clinics and other end users.
Immunotherapy Drugs Market Regional Analysis/Insights
The immunotherapy drugs market is analysed and market size insights and trends are provided by country, type of drug, therapy area and end user as referenced above.
The countries covered in the immunotherapy drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the immunotherapy drugs market due to the increasing FDA approvals. Furthermore, the rise in the prevalence of autoimmune diseases and cancer will further boost the growth of the immunotherapy drugs market in the region during the forecast period.
Asia-Pacific is projected to observe significant amount of growth in the immunotherapy drugs market due to the rise in the expenses to develop healthcare infrastructure. Moreover, the huge patient pool and growing cases of cancer is further anticipated to propel the growth of the immunotherapy drugs market in the region in the coming years.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The immunotherapy drugs market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for immunotherapy drugs market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the immunotherapy drugs market. The data is available for historic period 2010-2020.
Competitive Landscape and Immunotherapy Drugs Market Share Analysis
The immunotherapy drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to immunotherapy drugs market.
Some of the major players operating in the immunotherapy drugs market are
- Abbott (US)
- PerkinElmer Inc. (US)
- Illumina, Inc. (US)
- QIAGEN (Germany)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Novartis AG (Switzerland)
- AstraZeneca (UK)
- Pfizer Inc. (US)
- Sanofi (France)
- Johnson & Johnson Services, Inc. (India)
- AbbVie Inc. (US)
- Allergan (Ireland)
- Merck & Co., Inc. (US)
- Amgen Inc. (US)
- Thermo Fisher Scientific (US)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Takeda Pharmaceutical Company Limited. (Japan)
- GlaxoSmithKline plc (UK)
- Lupin Pharmaceuticals, Inc. (US)
- Lilly (US)
- Bristol-Myers Squibb Company (US)
- Medtronic (US)
- Bayer AG (Germany)
- Boehringer Ingelheim International GmbH (Germany)